%0 Journal Article
%T Dapagliflozin promotes browning of white adipose tissue through the FGFR1-LKB1-AMPK signaling pathway.
%A Lv Y
%A Zhao C
%A Jiang Q
%A Rong Y
%A Ma M
%A Liang L
%A Li W
%A Zhang J
%A Xu N
%A Wu H
%J Mol Biol Rep
%V 51
%N 1
%D 2024 Apr 21
%M 38644407
%F 2.742
%R 10.1007/s11033-024-09540-3
%X <B>BACKGROUND: </B>Obesity is associated with a wide variety of metabolic disorders that impose significant burdens on patients and society. The "browning" phenomenon in white adipose tissue (WAT) has emerged as a promising therapeutic strategy to combat metabolic disturbances. However, though the anti-diabetic drug dapagliflozin (DAPA) is thought to promote "browning," the specific mechanism of this was previously unclear.<BR><B>METHODS: </B>In this study, C57BL/6 J male mice were used to establish an obesity model by high-fat diet feeding, and 3T3-L1 cells were used to induce mature adipocytes and to explore the role and mechanism of DAPA in "browning" through a combination of in vitro and in vivo experiments.<BR><B>RESULTS: </B>The results show that DAPA promotes WAT "browning" and improves metabolic disorders. Furthermore, we discovered that DAPA activated "browning" through the fibroblast growth factor receptors 1-liver kinase B1-adenosine monophosphate-activated protein kinase signaling pathway.<BR><B>CONCLUSIONS: </B>These findings provide a rational basis for the use of DAPA in treating obesity by promoting the browning of white adipose tissue.